Vantictumab
Vantictumab is a monoclonal antibody designed for the treatment of cancer. It specifically targets the Wnt signaling pathway, which is often implicated in the proliferation and survival of cancer cells. By inhibiting this pathway, vantictumab aims to reduce tumor growth and prevent the spread of cancer.
Mechanism of Action[edit | edit source]
Vantictumab works by binding to Frizzled receptors, which are involved in the Wnt signaling pathway. The Wnt pathway plays a crucial role in cellular processes such as cell growth, differentiation, and migration. In many cancers, this pathway is abnormally activated, leading to uncontrolled cell proliferation and tumor development. By blocking Frizzled receptors, vantictumab inhibits the pathway, potentially leading to reduced tumor growth and metastasis.
Clinical Trials[edit | edit source]
Vantictumab has been evaluated in several clinical trials for its effectiveness and safety in treating various types of cancer, including breast cancer, pancreatic cancer, and non-small cell lung cancer. These studies assess not only the drug's ability to shrink tumors but also its side effects and overall impact on patients' quality of life.
Safety and Side Effects[edit | edit source]
As with any cancer therapy, vantictumab can cause side effects. The most common adverse effects reported in trials include fatigue, nausea, and diarrhea. More serious side effects may include neutropenia, a condition where neutrophil levels become dangerously low, making patients more susceptible to infections.
Development and Regulatory Status[edit | edit source]
Vantictumab is still under investigation and has not yet received approval from regulatory bodies such as the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA) in Europe. Ongoing research and clinical trials continue to evaluate its safety and efficacy.
Future Prospects[edit | edit source]
Research continues to explore the potential of vantictumab in combination with other therapies. Combining different therapeutic agents might enhance the overall effectiveness and manage the resistance often seen in monotherapy treatments. The future of vantictumab will depend on the outcomes of ongoing and future clinical trials.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
